Dr. Ting-Chao Chou is a distinguished Taiwanese-American theoretical biologist and pharmacologist whose pioneering work has fundamentally advanced quantitative approaches to drug development and cancer therapeutics. He earned his master's degree from the Pharmacological Institute of National Taiwan University College of Medicine before pursuing doctoral studies at Yale University, where he focused on the mathematical aspects of quantitative biology. Following a postdoctoral fellowship at Johns Hopkins University School of Medicine from 1970 to 1972, he joined Memorial Sloan Kettering Cancer Center as an assistant professor with academic affiliation through Cornell University Graduate School of Medical Sciences. His four-decade career at MSKCC culminated in his appointment as a full member and professor in 1988, where he directed the Preclinical Pharmacology Core Laboratory within the Molecular Pharmacology & Chemistry Program.
Dr. Chou's groundbreaking research centers on the development and application of the mass-action law principle to pharmacodynamics, resulting in the innovative MAL-BD/PD/CI/BI theoretical framework that has transformed quantitative analysis in drug combination studies. His pioneering work has yielded over 40 U.S. patents as either solo or collaborative inventor, including significant contributions to synthetic microtubule targeting epothilone compounds such as Fludelone and Iso-Oxazole-Fludelone which demonstrate promising efficacy against solid tumors and leukemias. Additionally, his research encompasses the development of novel immunosuppressants including Ardeemins and Ningalins for organ transplantation, and synthetic cyto-protective Panaxytriols inspired by traditional Chinese and Korean ginseng, designed to mitigate chemotherapy-induced toxicities such as peripheral neuropathy and alopecia. These innovations represent the practical application of his theoretical frameworks, translating mathematical principles into tangible therapeutic advances with significant clinical potential.
Following his retirement from MSKCC in 2013, Dr. Chou founded PD Science LLC in Paramus, New Jersey, to further promote and develop his theoretical approaches in pharmaceutical research and development. His MAL-BD/PD/CI/BI methodology has become increasingly influential in both academic and industrial settings, providing researchers with sophisticated tools for analyzing drug interactions and optimizing therapeutic regimens. Through PD Science, he continues to advance the field of pharmacodynamics, offering specialized software and consultation that implement his theoretical approaches to pharmaceutical companies and research institutions worldwide. Dr. Chou's enduring legacy lies in bridging theoretical mathematics with practical pharmacology, creating a robust quantitative foundation that continues to shape modern drug development strategies and combination therapy approaches across the global pharmaceutical landscape.
